New Zealand markets open in 3 hours 36 minutes

Kyverna Therapeutics, Inc. (KYTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.53-4.91 (-34.00%)
At close: 04:00PM EDT
9.63 +0.10 (+1.05%)
After hours: 07:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 410.89M
Enterprise value 51.94M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.14
Enterprise value/revenue 3.34k
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-68.34%
S&P500 52-week change 323.76%
52-week high 330.60
52-week low 38.80
50-day moving average 316.08
200-day moving average 320.91

Share statistics

Avg vol (3-month) 3503.98k
Avg vol (10-day) 31M
Shares outstanding 543.12M
Implied shares outstanding 665.65M
Float 822.54M
% held by insiders 110.77%
% held by institutions 181.90%
Shares short (15 May 2024) 42.73M
Short ratio (15 May 2024) 46.35
Short % of float (15 May 2024) 411.48%
Short % of shares outstanding (15 May 2024) 46.34%
Shares short (prior month 15 Apr 2024) 41.56M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -78.31M
Net income avi to common (ttm)-75.92M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)369.79M
Total cash per share (mrq)8.58
Total debt (mrq)10.85M
Total debt/equity (mrq)3.01%
Current ratio (mrq)17.17
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-66.48M
Levered free cash flow (ttm)N/A